SynthesisJAMA ophthalmology2024
Prevalence of Glaucoma Among US Adults in 2022.
Synthesis in JAMA ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Michigan Screening and Intervention for Glaucoma and Eye Health through Telemedicine Program: Impact on Vision, Follow-up, and Costs.Ophthalmology · 2025Trial
- Comparison of Visual Field Assessments Between the Humphrey Field Analyzer, Tempo, and Virtual Eye Elite Perimeters.Clinical ophthalmology (Auckland, N.Z.) · 2025Trial
- Patterns of Glaucoma Treatment Use in Asian American Patients With Primary Open-Angle Glaucoma.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026Article
- Large Language Models Approximate Inter-Expert Agreement in Glaucoma Suspect and Glaucoma Classification from Multimodal Data.Ophthalmology science · 2026Article
- [Experiences of glaucoma patients : Evaluation of the survey conducted by the Federal Association Glaucoma Self-help and the DOG Glaucoma Section].Die Ophthalmologie · 2026Article
- Retinal Arteriosclerosis and Fundus Photograph-Defined Glaucoma in Young Adults: Findings from the Gangnam Eye Cohort.Biomedicines · 2026Article
- Indications for Medical Cannabis and Their Alignment With US-Wide Disease Prevalences in the US' Largest Medical Cannabis Program: Cross-Sectional Study.JMIR public health and surveillance · 2026Article
- Modalities of vision restoration in optic neuropathies and retinal disease.Progress in retinal and eye research · 2026Review
- Clinic-based burden of glaucoma among Sahrawi refugees in the Tindouf camps.BMJ open ophthalmology · 2026Article
- Risk of Depression, Anxiety, and Suicidal Behavior in Older Adults With Severe Vision Loss.Journal of vitreoretinal diseases · 2026Article
- Optic Nerve Head Spatial Transcriptomic Change in Nonhuman Primate Early Experimental Glaucoma.Investigative ophthalmology & visual science · 2026Article
- Trends in First-Line Glaucoma Treatment from 2013 to 2024: A Multi-institutional and Multinational Cohort Study.Ophthalmology and therapy · 2026Article
- Bioengineered 3D Human Trabecular Meshwork Models for Outflow Physiology and Glaucoma Research.Bioengineering (Basel, Switzerland) · 2026Review
- Integrative Proteogenomic Analysis Identifies Genetically Supported Plasma Proteins, Metabolites, and Pathways in Glaucoma.Investigative ophthalmology & visual science · 2026Article
- From Regeneration Failure to Functional Restoration: Unlocking the Neuronal-Intrinsic Regenerative Capacity as a Therapeutic Frontier for Optic Neuropathy and Glaucoma.CNS neuroscience & therapeutics · 2026Review
- Camera-Agnostic Autonomous Diagnosis of Glaucomatous Optic Neuropathy using Macular Fundus Imaging and Machine Learning.medRxiv : the preprint server for health sciences · 2026Article
- Aggregate index of systemic inflammation and glaucoma status: population-based evidence with clinical validation.Frontiers in medicine · 2026Article
- Opportunistic Glaucoma Detection in a Diabetic Eye Screening Program: Yield and Feasibility in a Caribbean Population.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Efficacy of Netarsudil in Open and Closed Angle Glaucomas Within the Vietnamese Population: A Single-Center, Retrospective Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Dietary inflammatory potential and glaucoma susceptibility: a nationally representative study from NHANES.International journal of ophthalmology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Glaucoma is the leading cause of irreversible blindness worldwide and, in the US, disproportionately affects people from racial and ethnic minority groups. Glaucoma prevalence has not been estimated for the US in more than a decade, and state- and county-level estimates are not available. Objective: To estimate glaucoma and vision-affecting glaucoma prevalence by demographic factors and US state and county for the Centers for Disease Control and Prevention's Vision and Eye Health Surveillance System (VEHSS). Data Sources: This meta-analysis used data from the National Health and Nutrition Examination Survey (2005-2008), Medicare fee-for-service claims (2019), IBM MarketScan commercial insurance claims (2016), population-based studies of eye disease (1985-2003), and 2022 population estimates from the US Census Bureau. Study Selection: PubMed was searched for population-based studies of glaucoma prevalence published between 1991 and 2016. Data Extraction and Synthesis: Bayesian meta-regression methods were used to estimate the prevalence of glaucoma and vision-affecting glaucoma stratified by age, undifferentiated sex/gender (a measure that captures an unclear mix of aspects of sex and or gender), race and ethnicity, and US county and state. Main Outcomes and Measures: Prevalence of any type of glaucoma (open or closed angle) among people 18 years or older and vision-affecting glaucoma, defined as glaucoma and a visual field abnormality. Results: For 2022, an estimated 4.22 million people (95% uncertainty interval [UI], 3.46 million to 5.23 million) in the US were living with glaucoma, with a prevalence of 1.62% (UI, 1.33%-2.00%) among people 18 years or older and 2.56% (UI, 2.10%-3.16%) among people 40 years or older. An estimated 1.49 million people (UI, 1.17 million to 1.90 million) were living with vision-affecting glaucoma, with a prevalence of 0.57% (UI, 0.45%-0.73%) among people 18 years or older and 0.91% (UI, 0.71%-1.16%) among people 40 years or older. Prevalence of glaucoma among people 18 years or older ranged from 1.11% (UI, 0.89%-1.40%) in Utah to 1.95% (UI, 1.57%-2.39%) in Mississippi. Black adults had a prevalence of 3.15% (UI, 2.32%-4.09%) compared with 1.42% (UI, 1.10%-1.85%) among White adults; adults in the Hispanic and all other racial and ethnic categories combined had a prevalence of 1.56% (UI, 1.13%-2.06%). Conclusions and Relevance: This meta-analysis found that an estimated 2.56% of people 40 years or older have glaucoma, slightly more than estimated by previous studies. Black individuals are disproportionately affected. Prevalence estimates at the state and county level can help guide public health planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.